Enrichment of PIK3-AKT-MTOR pathway activation in hepatic metastases from breast cancer

Purpose: Little is known about the molecular signatures associated with specific metastatic sites in breast cancer. Using comprehensive multi-omic molecular profiling, we assessed whether alterations or activation of the PI3K-AKT-mTOR pathway is associated with specific sites of breast cancer metastasis. <p>Experimental Design: NGS-based whole exome sequencing was coupled with Reverse Phase Protein Microarray (RPPA) functional signaling network analysis to explore the PI3K-AKT-mTOR axis in 32 pretreated breast cancer metastases. RPPA-based signaling data were further validated in an independent cohort of 154 metastatic lesions from breast cancer and 101 un-matched primary breast tumors. The proportion of cases with PI3K-AKT-mTOR genomic alterations or signaling network activation were compared between hepatic and non-hepatic lesions.</p> <p>Results: PIK3CA mutation and activation of AKT (S473) and p70S6K (T389) were detected more frequently among liver metastases than non-hepatic lesions (p<0.01, p=0.056, and p=0.053 respectively). However, PIK3CA mutations alone were insufficient in predicting protein activation (p=0.32 and p=0.19 for activated AKT and p70S6K respectively). RPPA analysis of an independent cohort of 154 tumors confirmed the relationship between pathway activation and hepatic metastasis (AKT (S473), mTOR (S2448), and 4EBP1 (S65); p<0.01, p=0.02, and p=0.01 respectively). Similar results were also seen between liver metastases and primary breast tumors (AKT (S473) p<0.01, mTOR (S2448) p<0.01, 4EBP1 (S65) p=0.01). This signature was lost when primary tumors were compared to all metastatic sites combined.</p> <p>Conclusions: Breast cancer patients with liver metastasis may represent a molecularly homogenized cohort with increased incidence of PIK3CA mutations and activation of the PI3K-AKT-mTOR signaling network.

from Cancer via ola Kala on Inoreader http://ift.tt/2oyeSuO
via IFTTT